Capitalizing a Cure : : how finance controls the price and value of medicines / / Victor Roy.
"Capitalizing a Cure takes us into the struggle over accessing a medical breakthrough to investigate the power of finance over business, biomedicine, and public health. When sofosbuvir-based medicines launched in 2013, they promised a cure for millions of patients worldwide with hepatitis C. Bu...
Saved in:
VerfasserIn: | |
---|---|
Place / Publishing House: | Oakland, California : : University of California Press,, 2023. |
Year of Publication: | 2023 |
Language: | English |
Physical Description: | 1 online resource |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993580998804498 |
---|---|
ctrlnum |
(CKB)5860000000285395 (NjHacI)995860000000285395 (DE-B1597)627970 (DE-B1597)9780520388727 (OCoLC)1374540806 (EXLCZ)995860000000285395 |
collection |
bib_alma |
record_format |
marc |
spelling |
Roy, Victor, author. Capitalizing a Cure : how finance controls the price and value of medicines / Victor Roy. Oakland, California : University of California Press, 2023. 1 online resource text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on publisher supplied metadata and other sources. "Capitalizing a Cure takes us into the struggle over accessing a medical breakthrough to investigate the power of finance over business, biomedicine, and public health. When sofosbuvir-based medicines launched in 2013, they promised a cure for millions of patients worldwide with hepatitis C. But their sticker shock-the drug was dubbed "the $1,000-a-day pill"-intensified a global debate over the pricing of new medicines. Weaving extensive historical research with insights from political economy and science and technology studies, Victor Roy demystifies an oft-missed dynamic in this debate: the reach of financialized capitalism into how medicines are made, priced, and valued. His account travels between public and private labs, Wall Street and corporate boardrooms, public health meetings and health centers to trace the ways sofosbuvir-based medicines became financial assets dominated by strategies of speculation and extraction at the expense of access and care. Provocative and sobering, this book illuminates the harmful impact of allowing financial markets to supersede democracy and human health and points to the necessary work of building more equitable futures."-- Provided by publisher. In English. Preface : pandemics, Wall Street, and the value playbook -- Introduction : the politics of drug pricing and the value of a cure -- Capitalizing science : public knowledge into pharmaceutical assets -- Capitalizing drugs : shareholder power and the cannibalizing company -- Capitalizing health : the struggle over value and treatment access -- From financialization to public purpose for health -- Conclusion : reckoning with pharmaceutical value in crisis times. This eBook is made available Open Access under a CC BY-NC-ND 4.0 license: https://creativecommons.org/licenses/by-nc-nd/4.0 https://www.degruyter.com/dg/page/open-access-policy Drugs Prices United States. Gilead Sciences (Firm) 0-520-38871-2 |
language |
English |
format |
eBook |
author |
Roy, Victor, |
spellingShingle |
Roy, Victor, Capitalizing a Cure : how finance controls the price and value of medicines / Preface : pandemics, Wall Street, and the value playbook -- Introduction : the politics of drug pricing and the value of a cure -- Capitalizing science : public knowledge into pharmaceutical assets -- Capitalizing drugs : shareholder power and the cannibalizing company -- Capitalizing health : the struggle over value and treatment access -- From financialization to public purpose for health -- Conclusion : reckoning with pharmaceutical value in crisis times. |
author_facet |
Roy, Victor, |
author_variant |
v r vr |
author_role |
VerfasserIn |
author_sort |
Roy, Victor, |
title |
Capitalizing a Cure : how finance controls the price and value of medicines / |
title_sub |
how finance controls the price and value of medicines / |
title_full |
Capitalizing a Cure : how finance controls the price and value of medicines / Victor Roy. |
title_fullStr |
Capitalizing a Cure : how finance controls the price and value of medicines / Victor Roy. |
title_full_unstemmed |
Capitalizing a Cure : how finance controls the price and value of medicines / Victor Roy. |
title_auth |
Capitalizing a Cure : how finance controls the price and value of medicines / |
title_new |
Capitalizing a Cure : |
title_sort |
capitalizing a cure : how finance controls the price and value of medicines / |
publisher |
University of California Press, |
publishDate |
2023 |
physical |
1 online resource |
contents |
Preface : pandemics, Wall Street, and the value playbook -- Introduction : the politics of drug pricing and the value of a cure -- Capitalizing science : public knowledge into pharmaceutical assets -- Capitalizing drugs : shareholder power and the cannibalizing company -- Capitalizing health : the struggle over value and treatment access -- From financialization to public purpose for health -- Conclusion : reckoning with pharmaceutical value in crisis times. |
isbn |
9780520388727 0-520-38871-2 |
callnumber-first |
H - Social Science |
callnumber-subject |
HD - Industries, Land Use, Labor |
callnumber-label |
HD9666 |
callnumber-sort |
HD 49666.4 R69 42023 |
geographic_facet |
United States. |
illustrated |
Not Illustrated |
dewey-hundreds |
300 - Social sciences |
dewey-tens |
330 - Economics |
dewey-ones |
338 - Production |
dewey-full |
338.4361510973 |
dewey-sort |
3338.4361510973 |
dewey-raw |
338.4361510973 |
dewey-search |
338.4361510973 |
oclc_num |
1374540806 |
work_keys_str_mv |
AT royvictor capitalizingacurehowfinancecontrolsthepriceandvalueofmedicines |
status_str |
n |
ids_txt_mv |
(CKB)5860000000285395 (NjHacI)995860000000285395 (DE-B1597)627970 (DE-B1597)9780520388727 (OCoLC)1374540806 (EXLCZ)995860000000285395 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Capitalizing a Cure : how finance controls the price and value of medicines / |
_version_ |
1796652748439027713 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03083nam a2200397 i 4500</leader><controlfield tag="001">993580998804498</controlfield><controlfield tag="005">20230616094907.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr#|||||||||||</controlfield><controlfield tag="008">230325s2023 cau o 000 0 eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780520388727</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1525/9780520388727</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5860000000285395</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)995860000000285395</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-B1597)627970</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-B1597)9780520388727</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1374540806</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995860000000285395</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="043" ind1=" " ind2=" "><subfield code="a">n-us---</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">cau</subfield><subfield code="c">US-CA</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">HD9666.4</subfield><subfield code="b">.R69 2023</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED050000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">338.4361510973</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Roy, Victor,</subfield><subfield code="e">author.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Capitalizing a Cure :</subfield><subfield code="b">how finance controls the price and value of medicines /</subfield><subfield code="c">Victor Roy.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oakland, California :</subfield><subfield code="b">University of California Press,</subfield><subfield code="c">2023.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">"Capitalizing a Cure takes us into the struggle over accessing a medical breakthrough to investigate the power of finance over business, biomedicine, and public health. When sofosbuvir-based medicines launched in 2013, they promised a cure for millions of patients worldwide with hepatitis C. But their sticker shock-the drug was dubbed "the $1,000-a-day pill"-intensified a global debate over the pricing of new medicines. Weaving extensive historical research with insights from political economy and science and technology studies, Victor Roy demystifies an oft-missed dynamic in this debate: the reach of financialized capitalism into how medicines are made, priced, and valued. His account travels between public and private labs, Wall Street and corporate boardrooms, public health meetings and health centers to trace the ways sofosbuvir-based medicines became financial assets dominated by strategies of speculation and extraction at the expense of access and care. Provocative and sobering, this book illuminates the harmful impact of allowing financial markets to supersede democracy and human health and points to the necessary work of building more equitable futures."--</subfield><subfield code="c">Provided by publisher.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">In English.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Preface : pandemics, Wall Street, and the value playbook -- Introduction : the politics of drug pricing and the value of a cure -- Capitalizing science : public knowledge into pharmaceutical assets -- Capitalizing drugs : shareholder power and the cannibalizing company -- Capitalizing health : the struggle over value and treatment access -- From financialization to public purpose for health -- Conclusion : reckoning with pharmaceutical value in crisis times.</subfield></datafield><datafield tag="540" ind1=" " ind2=" "><subfield code="a">This eBook is made available Open Access under a CC BY-NC-ND 4.0 license:</subfield><subfield code="u">https://creativecommons.org/licenses/by-nc-nd/4.0</subfield><subfield code="u">https://www.degruyter.com/dg/page/open-access-policy</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drugs</subfield><subfield code="x">Prices</subfield><subfield code="z">United States.</subfield></datafield><datafield tag="610" ind1="2" ind2="0"><subfield code="a">Gilead Sciences (Firm)</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">0-520-38871-2</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-10-04 16:23:04 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2023-02-11 21:29:23 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5343018690004498&Force_direct=true</subfield><subfield code="Z">5343018690004498</subfield><subfield code="b">Available</subfield><subfield code="8">5343018690004498</subfield></datafield></record></collection> |